Previous 10 | Next 10 |
Summary Triple-digit growth in top-line sales for the quarter and the year evidence the market's approval for TransMedics Group, Inc.'s offerings. TransMedics Group is addressing operational efficiencies in its transportation network. I am now looking for another 40% upside potentia...
Summary TransMedics reported its Q4 earnings highlighted by accelerating growth. The company's organ care system platform is gaining market adoption as a superior alternative to traditional cold storage methods. An expanding national network of devices supports a positive long-term ...
Summary TransMedics has been blowing away expectations in 2022. After slowly delivering on its potential in recent years, last year has been spectacular. The stock has been unleashed ever since, as I remain a somewhat more cautious (at these levels) believer. In May of las...
If you've been looking for stocks that are beating the market, you've probably come across a company called TransMedics Group (NASDAQ: TMDX) . This high-growth stock has been outperforming the broad market by a mile with gains of around 386% over the past 12 months. What is it about t...
The latest quarterly earnings report from healthcare equipment company TransMedics Group (NASDAQ: TMDX) brought a great many bulls back to the stock. On the back of convincing beats on analyst estimates plus strong guidance, the share price was up nearly 18% week to date as of early Frida...
TransMedics Group, Inc. (TMDX) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Brian Johnston – Gilmartin Group Waleed Hassanein – President and Chief Executive Officer Stephen Gordon – Chief Financial Officer ...
TransMedics Group press release ( NASDAQ: TMDX ): Q4 GAAP EPS of -$0.21 beats by $0.11 . Revenue of $31.4M (+223.7% Y/Y) beats by $7.8M . Expects total revenue for full-year 2023 to be in the range of $138 million to $145 million. The consensus estimate i...
TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire ANDOVER, Mass. , Feb. 22, 2023 /PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy fo...
TransMedics Group ( NASDAQ: TMDX ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, after market close. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $23.6M (+143.3% Y/Y). Over the last 2 years, TMDX has beaten EPS estima...
ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be partic...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...